Real-World Outcomes of Resected EGFR-Mutated NSCLC Patients Treated With Adjuvant EGFR-TKI in China

Recruiting now

Conditions studied: Lung Cancer

In brief

This is a multi-centre, observational study, with retrospective data collection and prospective active follow-up. The aim is to measure the treatment pattern and real-world outcomes of EGFR-TKI as an adjuvant therapy in patients with early-stage EGFR-mutated NSCLC. The study period ranges from July 1st, 2022 to June 30th, 2031. Approximately 2,000 patients will be enrolled from 15 sites in China.

Key facts

Study ID

NCT07593248

Run by

AstraZeneca

People needed

2000

Starts

2026-06-22

Expected to finish

2031-06-30

Last updated by the study team

2026-07-09

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosed stage IB-III NSCLC on or prior to the index date;
• Initiated adjuvant EGFR-TKI from July 1st, 2023 to June 30th, 2026

Where it is running

• Research Site — Guangzhou, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.